Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

American Electric Power Company

Canadian Imperial Bank of Commerce

Cisco Systems

Diageo

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Philip Morris

TotalEnergies SE

ViacomCBS

WestRock

Exxon Mobil

Dividend Income Summary: Bert's October 2021 Report

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q1 Fiscal 2022 Results - Earnings Call Transcript

Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.

Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates

Cardinal (CAH) delivered earnings and revenue surprises of -2.27% and 5.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Misses Q1 Earnings Estimates

Cardinal Health (NYSE: CAH) reported Q1 FY22 adjusted EPS of $1.29, down from $1.51 a year ago, missing the Street estimate of $1.33. Q1 sales increased 13% Y/Y to $44 billion, beating the consensus estimate of $41.93 billion.

Cardinal Health Post Mixed Q1 Earnings; Reaffirms FY22 Adjusted EPS Outlook

Shares of Cardinal Health Inc. CAH, +0.18% rose 1.5% in premarket trading Tuesday, after the drug distributor and make of lab products reported fiscal first-quarter profit that missed expectations, as supply chain costs weighed on its medical business, but revenue rose above forecasts. The company swung to net income of $271 million, or 94 cents a share, from a loss of $253 million, or 86 cents a share, in the year-ago period.

Cardinal Health stock gains as profit misses expectations but revenue beats and outlook affirmed

DUBLIN, Ohio, Nov. 9, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2022 revenues of $44.0 billion, an increase of 13% from the first quarter of last year. First quarter GAAP operating earnings were $415 million and GAAP diluted earnings per share (EPS) were $0.94.

Cardinal Health Reports First Quarter Fiscal 2022 Results

Amcor Plc

Chevron

Con Ed

National Retail Properties

Old Republic International

People's United Financial

South Jersey Industries

AT&T

Telephone and Data Systems

"S&P High Yield Dividend Aristocrats index is designed to measure the performance of companies within the S&P Composite 1500 that have consistently increased dividends every year for at least 20 years." - spindices.com.

112 S&P High Yield Dividend Aristocrats Deliver More Dog Per Dollar

DUBLIN, Ohio, Nov. 4, 2021 /PRNewswire/ -- Biologics are the fastest growing class of drugs in the U.S.; they bring innovative, life-changing treatments to patients with cancer and chronic diseases. Due to exclusive patents, they are also very expensive and out of reach for many.

Biosimilars 101: A Q&A with Sonia T. Oskouei, Cardinal Health Vice President of Biosimilars

Bank of Nova Scotia

Chimera Investment

Coinbase

Eastman Chemical

Gap Inc

Coca-Cola

MDU Resources Group

Medical Properties Trust

NetApp

Oracle

Occidental Petroleum

South32 Ltd

Visa

In October, we (my wife and I) received a total of $966.97 of dividend income.

Dividend Income Summary: Lanny's October 2021 Summary

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #POCUS--Exo (pronounced “echo”) is expanding its board of directors and adding key industry leaders to take POCUS ultrasound imaging everywhere.

Exo Adds Key Industry Leaders to Its Board and Executive Leadership Team

Aflac

Franklin Resources

Hormel Foods

Johnson & Johnson

McKesson

Medtronic

NextEra Energy

Procter & Gamble

V.F.

Walgreens

S&P 500 dividend aristocrats possess pretty safe dividends. All 65 of them have paid out higher disbursements for at least 25 straight years. We decided to put together our Buy list for the top six to purchase right now.

The Dividend Aristocrat 6-Pack Buy List

DUBLIN, Ohio, Oct. 28, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has been awarded a $750,000 contract by the U.S. Food and Drug Administration (FDA) to implement an 18-month real world evidence (RWE) study as part of the agency's efforts to advance the applicability of RWE in regulatory decision-making. The funding, which will support the project "Assessment of a Novel Methodology for Endpoints Assessing Response to Lymphoma Treatment in Real-World Studies," will evaluate the accuracy of real-world data (RWD) for lymphoma tumor response compared to blinded independent central review, the gold standard in randomized clinical trials.

Cardinal Health Awarded FDA Funding to Assess Real World Evidence Results Against Clinical Trials

Altria

The short "taper tantrum 2.0" lasted a few weeks and saw stocks fall just 5.2%. We're now back to record highs and a 26% historically overvalued market. Fortunately, it will always be a market of stocks and not a stock market. At any given time, 40% of blue-chips are trading at fair value or better.

My, Oh My, 3 High-Yield Dividend Aristocrat Strong Buys

DUBLIN, Ohio, Oct. 25, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today its cancer screening offerings from FUJIFILM Healthcare Americas Corporation and Polymedco that can be done either outside of a doctor's office or with less invasive procedures can help combat the increase in cancer-related deaths due to late-stage diagnoses1 from pandemic-related delays. "The pandemic has changed the landscape of traditional diagnostic methods and is driving the healthcare industry to evaluate screenings differently," added Chris Kerski, general manager and senior vice president of Cardinal Health Laboratory Products.

Cardinal Health expands solutions to mitigate missed cancer screenings

Cardinal Health's (CAH) company, OptiFreight Logistics', recent collaboration with Journey Biosciences to help patients with respect to long-term diabetes care.

Cardinal Health's (CAH) Unit Ties Up to Boost Diabetes Care

Cardinal Health's share price has been beaten down due to what I see as being transient and one-time events. Pressures are expected to ease in the second half of its current fiscal year, with growth normalizing in the pharma and medical segments.

Cardinal Health: Deep Value, High Yield, Are You Putting Cash To Work?

Target

Western Union

Make the most of your money with these income-producing investments.

Got $10,000? These 3 Dividend Stocks Are on Sale

LEBANON, N.H., Oct. 14, 2021 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company with an innovative proactive diagnostic screening technology for high risk kidney complications, including Diabetic Kidney Disease (DKD), today announced a collaboration with Cardinal Health (NYSE: CAH) OptiFreight® Logistics that will increase control and visibility across every transportation modality.

Journey Biosciences and Cardinal Health OptiFreight® Logistics Collaborate to Improve Long-Term Diabetes Care

Enbridge

At least one of them has been known to bring a smile to faces.

3 Top Dividend Aristocrat Stocks for $55 or Less

DUBLIN, Ohio, Oct. 12, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today its Strategic Stock Solution now serves nearly 40 hospitals and health systems nationwide, just one year after its launch. In October last year, the U.S. healthcare system faced what was one of the deadliest surges of the pandemic to date1.

News for Cardinal Health Stock (CAH)